US20030176805A1 - Method for detecting alpha-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient - Google Patents
Method for detecting alpha-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient Download PDFInfo
- Publication number
- US20030176805A1 US20030176805A1 US10/297,424 US29742403A US2003176805A1 US 20030176805 A1 US20030176805 A1 US 20030176805A1 US 29742403 A US29742403 A US 29742403A US 2003176805 A1 US2003176805 A1 US 2003176805A1
- Authority
- US
- United States
- Prior art keywords
- oxoaldehydes
- serum
- patient
- blood
- breath air
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- 210000002381 plasma Anatomy 0.000 title claims abstract description 18
- 210000004369 blood Anatomy 0.000 title claims abstract description 17
- 239000008280 blood Substances 0.000 title claims abstract description 17
- 210000002966 serum Anatomy 0.000 title claims abstract description 13
- 238000004458 analytical method Methods 0.000 claims abstract description 7
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 claims description 34
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- 229930189936 Glyoxalase Natural products 0.000 claims description 3
- 229940015043 glyoxal Drugs 0.000 claims description 3
- 238000001212 derivatisation Methods 0.000 claims description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002620 polyvinyl fluoride Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 0 CC1=C([N+](=O)[O-])C=C([N+](=O)[O-])C=C1.[1*]C([2*])=NNC1=C([N+](=O)[O-])C=C([N+](=O)[O-])C=C1.[1*]C([2*])=O.[OH3+] Chemical compound CC1=C([N+](=O)[O-])C=C([N+](=O)[O-])C=C1.[1*]C([2*])=NNC1=C([N+](=O)[O-])C=C([N+](=O)[O-])C=C1.[1*]C([2*])=O.[OH3+] 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/082—Evaluation by breath analysis, e.g. determination of the chemical composition of exhaled breath
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/497—Physical analysis of biological material of gaseous biological material, e.g. breath
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Abstract
The invention relates to a method for detecting α-oxoaldehydes in whole blood, blood plasma and/or in serum of a patient, in which a breath air sample is analysed for the presence of at least one α-oxoaldehyde and the presence of α-oxoaldehydes in the whole blood, blood plasma and/or serum of the patient is deduced from the analysis result.
Description
- The present invention relates to a method for detecting α-oxoaldehydes in whole blood, in the blood plasma and/or in the serum of patients.
- Complications arising as a result of long-standing diabetes diseases, i.e. insulin-dependent or non-insulin-dependent diabetes, such as kidney damage or clouding of the lenses of the eye, can only be detected with difficulty and often only at a late stage. Joint responsibility for these complications and consequential illnesses often lies with reactive metabolic products which, together with collagen, enzymes or other cellular components, form glycolates and can act as cell toxins by means of this mechanism. Corresponding markers for this disease can be detected according to the state of the art only via complex blood analytics in the laboratory.
- In the last three to four years, experiments for elucidating the consequential illnesses in the course of long-standing diabetes have shown that the cytotoxic α-oxoaldehydes play an important and causal role (Beisswenger et al. (1999) Diabetes, Volume 48, p. 198-202). Hence in this connection, in particular the role of α-oxoaldehydes such as methylglyoxal, glyoxal or 3-deoxyglucuron is discussed. These materials are formed in the red blood corpuscles and occur in very small concentrations in the whole blood, in the blood plasma and in the serum.
- In this connection, the α-oxoaldehyde methylglyoxal is of particular interest. Methylglyoxal can arise from triose phosphate, the metabolisation of ketone bodies and also during the metabolisation of threonine and is broken down further by means of glyoxalase. Methylglyoxal then reacts with proteins with the formation of imidazolone derivatives and bis-lysyl crosslinkings. This crosslinking of the proteins can lead to stabilisation of collagen and as a result to the thickening of membranes. Hence, these reactions explain at least part of diabetic complications, such as kidney failure and lens clouding.
- The unaccompanied blood sugar determination, as is normal to date in the case of diabetics, gives no direct conclusion as to the momentary methylglyoxal concentration in the whole blood, in the plasma or in the serum.
- According to the state of the art, the determination of α-oxoaldehydes is hence effected exclusively invasively, i.e. from the blood plasma. In the case of patients with insulin-dependent diabetes, there could be detected by Thornally T. J., “Advanced Glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress” Endocrinology and Metabolism, 1996, 3, 149-166, a methylglyoxal concentration directly in the plasma which was five to six times higher compared to healthy comparative experimentees and two to three times higher in the case of patients with insulin-dependent diabetes. Alternatively, a determination of α-oxoaldehyde would be possible in the urine, but is not described in the literature, since the physiologically conditioned very low concentrations in the urine which are to be expected, would require too high an analysis complexity. Hence a direct determination of the α-oxoaldehydes in the plasma is required.
- As a result of these examination methods according to the state of the art, regular checks and a possible needs-orientated dosing of medicines for targeted reduction of α-oxoaldehydes, such as methylglyoxal, in the whole blood, blood plasma and serum are very expensive.
- WO 98/57 145 A1 describes a method for early detection of biological conditions, such as illnesses, by means of the analysis of suitable gaseous samples.
- WO 99/56 790 A2 describes a diagnostic kit for implementation of breath tests which are used for diabetic diagnosis.
- DD 219 287 A1 describes a measuring apparatus for checking blood sugar in the case of diabetics based on selective determination of the concentration of acetone in the breath gas on the basis of the radiation absorption using a measuring cuvette, filters, lenses and a power supply unit.
- These methods according to the state of the art are consequently very complex and expensive and therefore have not been suitable to date for a regular routine check for determining the α-oxoaldehyde content in the whole blood, blood plasma or serum.
- The object of the present invention is therefore to make available a method for detecting α-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient which can be implemented in a simple, economical and reliable manner.
- This object is achieved by means of a method with the features of claim 1. Advantageous developments of the method according to the invention are given in the dependent claims.
- The method according to the invention is based on the fact that for instance an examination is not performed on the patient himself but merely a breath air sample (i.e. breath gas and/or breath condensate) of the patient is examined. With this method, α-oxoaldehydes are also detected in the breath air. Obviously α-oxoaldehydes, which are present mainly in the blood plasma, can in addition easily pass through a membrane, so that these can be detected in the breath gas or in the breath condensate. Furthermore, in contrast to other known markers, such as acetone, they are metabolically specific and do not occur ubiquitously in air. Hence, a simple, economical and reliable, regular and non-invasive monitoring of the a-oxoaldehyde formation in the whole blood, blood plasma and serum is possible in the case of diabetics so that, by means of suitable medication, the risk of possible consequential illnesses of diabetes can be reduced. Hence, the possibility exists, in the case of patients with long-standing diabetes, of introducing new strategies for avoidance of diabetic complications. For example, it is possible that the concentration of α-oxoaldehydes in the blood can be reduced by administering so-called scavenger compounds. Therapies of this type are supported by the non-invasive test method according to the invention and are possible on a merely routine basis.
- Taking of the sample can be effected either by means of blowing into a corresponding sampling bag and/or suitable sample containers or by directing the breath air through an impinger. This impinger can be filled with a derivatisation medium for direct detection (by means of fluorescence or photometrically) or for a chromatographic determination. The filling of the impingers with reagents for electrochemical, spectrometric (e.g. IR spectrometric), enzymatic or immunochemical detection is also possible.
- One detection method resides in the enzymatic conversion of methylglyoxal with glyoxalase into lactate and the subsequent determination of lactate with a modified sensor.
- It is thereby important in the present invention, that all the components of a breath air sample, i.e. both the breath air and the breath condensate, are suitable for analysis of the α-oxoaldehyde content.
- An example of the method according to the invention is described subsequently.
- In this example, a breath air sample of a female patient with Type II diabetes was taken and examined for the α-oxoaldehydes glyoxal and methylglyoxal. The DNPH method according to Zurek et al., Analyst 1999, Vol. 124, p. 1291-1295, was used as examination method.
- The sampling of the breath air was implemented as follows: via a mouthpiece with a tube, a sample bag (here a Tedlar® bag) with a volume of 30 litres was blown into by the test person/patient.
- The sampling via a Tedlar bag was implemented in order subsequently to be able to conduct a defined volume across the collection phase.
- Subsequent to the sampling, a defined air volume (20 l in the case of a volume flow <2 l/min) was sucked by means of a pump out of the bag via a cartouche which contains the collected material. The commercially available cartouche was filled with silica gel covered with 2,4-dinitrophenylhydrazine (Supelco: article no. 505358) as collected material. The α-oxoaldehydes reacted according to the following equation into 2,4-dinitrohydrazones and were retained on the silica gel.
- The resultant derivatives were subsequently eluted with 4 ml of acetonitrile from the cartouche and the obtained eluate was reduced to dryness. The remaining residue was dissolved again with 500 μl of acetonitrile. An aliquot of 20 μl was transferred into the HPLC system for analysis.
- An HPLC method according to the principle of reversed phase chromatography was used for analysis, with the following methodical parameters:
- Column: Hypersil BDS C18,
column length 10 cm, column diameter: 4 mm, particle size: 3 μm - Mobile phase: a mixture of acetonitrile and water, volume flow of 0.5 ml/min
- Starting conditions: a mixture of acetonitrile and water (50:50; volume ratios)
- Gradient: constant starting conditions over 10 minutes, then within 27 minutes to a volume proportion of acetonitrile of 100%. The data were detected by means of UV detection at 360 and 404 nm and recorded with a Hewlett Packard Chem-Station.
- FIG. 1:
- In order to protect the identification of the substances, a part of the eluate of the collection cartouche was analysed under the above-described conditions with an HPLC system, which in addition to the UV detector had a mass-spectrometric detector available (FIG. 1). The latter permits the identification of the substances by means of their molecular mass and also by means of the disintegration of the molecule into characteristic molecular fragments.
- Defined quantities of the derivatives of the α-oxoaldehydes were added to a further part of the eluate and the solution was analysed by means of HPLC and UV detection (principle of standard addition) (FIG. 2). Dependent upon the added quantity of derivative, the corresponding signal of the compound in the chromatogram is increased and thus the identification is confirmed.
- In FIG. 1, the peak for acetone and the peak for methylglyoxal can immediately be detected. Hence, it is shown that the metabolic product methylglyoxal can be detected also in the breath air sample and hence non-invasively and immediately indicates, on the basis of a metabolic specificity, the presence of methylglyoxal in the blood plasma of the patient. Since methylglyoxal does not occur ubiquitously, distortions of the measurements and falsifications of the measurement results due to the surroundings of the patient are not to be expected.
- During further comparative tests with healthy comparative experimentees, no α-oxoaldehyde was able to be detected to date in their breath air.
- As an example, the breath air samples of healthy comparative experimentees were examined corresponding to the above-described method. FIG. 3 shows the resultant chromatogram for a healthy experimentee. No evaluable signal can be detected in the retention time region of the α-oxoaldehydes. After addition of a methylglyoxal standard a signal appeared in 19.50 minutes in the chromatogram, as is shown in FIG. 4.
Claims (9)
1. Method for detecting α-oxoaldehydes in whole blood, blood plasma and/or serum of a patient, a breath air sample being analysed for the presence of at least one α-oxoaldehyde and the presence of α-oxoaldehydes in the whole blood, blood plasma and/or serum of the patient being deduced from the analysis result.
2. Method according to claim 1 , the concentration of α-oxoaldehydes in the breath air sample being determined and the concentration of α-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient being deduced therefrom.
3. Method according to claim 1 or 2, methylglyoxal, glyoxal and/or 3-deoxyglucuron being detected as α-oxoaldehyde.
4. Method according to one of the claims 1 to 3 , the breath air sample being enclosed in a sample bag and/or in a suitable sample container and/or being directed through an impinger.
5. Method according to one of the claims 1 to 4 , the α-oxoaldehydes in the breath air sample being derivatised by means of a derivatisation medium and the resulting derivatives being determined.
6. Method according to claim 5 , the derivatives being detected fluorometrically, photometrically and/or chromatographically.
7. Method according to one of the claims 1 to 4 , the α-oxoaldehydes in the breath air sample being determined by the α-oxoaldehydes being detected electrochemically, spectrometrically, enzymatically and/or immunochemically.
8. Method according to one of the claims 1 to 4 , the a-oxoaldehydes in the breath air sample being determined mass-spectrometrically.
9. Method according to one of the claims 1 to 4 , methylglyoxal which is contained in the breath air sample being converted into lactate with glyoxalase and subsequently the lactate being detected with a sensor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10028548A DE10028548C1 (en) | 2000-06-09 | 2000-06-09 | Method for the detection of alpha-oxoaldehydes in whole blood, blood plasma and / or serum of a patient |
| DE100-28-548.1 | 2000-06-09 | ||
| PCT/EP2001/006101 WO2001094942A1 (en) | 2000-06-09 | 2001-05-29 | Method for detecting alpha-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20030176805A1 true US20030176805A1 (en) | 2003-09-18 |
| US6884223B2 US6884223B2 (en) | 2005-04-26 |
Family
ID=7645215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/297,424 Expired - Fee Related US6884223B2 (en) | 2000-06-09 | 2001-05-29 | Method for detecting α-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6884223B2 (en) |
| EP (1) | EP1287356B1 (en) |
| JP (1) | JP2004501366A (en) |
| KR (1) | KR20030014691A (en) |
| AT (1) | ATE262179T1 (en) |
| AU (1) | AU2001263943A1 (en) |
| DE (2) | DE10028548C1 (en) |
| RU (1) | RU2002132381A (en) |
| WO (1) | WO2001094942A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080210879A1 (en) * | 2005-07-11 | 2008-09-04 | Maintenance Securite Installation Service | Method for Controlling Leakage Rate of Active Carbon Filters |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10134568C2 (en) * | 2001-07-16 | 2003-07-24 | Inst Chemo Biosensorik | Method for the quantitative determination of alpha-oxoaldehyde |
| DE10202893A1 (en) * | 2002-01-25 | 2003-08-07 | Inst Chemo Biosensorik | Method for the specific determination of methylglyoxal in liquid and / or gaseous samples |
| AT14763U1 (en) * | 2008-10-16 | 2016-05-15 | Darwin Gmbh | Set and method for obtaining a breathing air sample |
| US9626650B2 (en) | 2011-04-14 | 2017-04-18 | Elwha Llc | Cost-effective resource apportionment technologies suitable for facilitating therapies |
| US10445846B2 (en) | 2011-04-14 | 2019-10-15 | Elwha Llc | Cost-effective resource apportionment technologies suitable for facilitating therapies |
| US8816814B2 (en) | 2011-08-16 | 2014-08-26 | Elwha Llc | Systematic distillation of status data responsive to whether or not a wireless signal has been received and relating to regimen compliance |
| RU2476873C1 (en) * | 2011-08-22 | 2013-02-27 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Method of determining content of oestrogen and dexpanthenol in two-component medical drug by hplc |
| RU2475733C1 (en) * | 2011-08-22 | 2013-02-20 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Method of determining content of troxerutin, dexpanthenol, benzocaine and methyl parahydroxybenzoate in medical drug by hplc |
| RU2517761C1 (en) * | 2012-11-08 | 2014-05-27 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Method of determining content of hydroxymethyl quinoxyline dioxide and impurities thereof by hplc |
| CN111398460A (en) * | 2020-04-02 | 2020-07-10 | 必睿思(杭州)科技有限公司 | Method for detecting content of aldehydes and ketones in human exhaled air |
| CN112255354B (en) * | 2020-09-11 | 2021-09-10 | 广州医科大学附属第一医院 | Characteristic substance for diagnosing Marneffei panuliasis and screening method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3792272A (en) * | 1973-01-12 | 1974-02-12 | Omicron Syst Corp | Breath test device for organic components, including alcohol |
| US5174959A (en) * | 1986-12-22 | 1992-12-29 | Abbott Laboratories | Breath component monitoring device |
| US5601079A (en) * | 1992-03-12 | 1997-02-11 | Wong; Jacob Y. | Non-invasive quantification of glucose control, aging, and advanced maillard products by stimulated fluorescence |
| US5618734A (en) * | 1993-09-29 | 1997-04-08 | Kureha Chemical Industry Co., Ltd. | Method for measuring 3-deoxyglucosone derivatives in a sample |
| US6467333B2 (en) * | 1998-06-19 | 2002-10-22 | California Institute Of Technology | Trace level detection of analytes using artificial olfactometry |
| US6620107B2 (en) * | 1997-03-06 | 2003-09-16 | Osmetech Plc | Detection of conditions by analysis of gases or vapours |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD219287A1 (en) * | 1983-11-02 | 1985-02-27 | Adw Ddr | MEASURING DEVICE FOR CONTROLLING BLOOD SUGAR |
| US5494562A (en) * | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
| WO1998057145A1 (en) * | 1997-06-10 | 1998-12-17 | Quadrivium, L.L.C. | System and method for detection of a biological condition |
| GB9711994D0 (en) | 1997-06-11 | 1997-08-06 | Glaxo Group Ltd | Chemical compounds |
| US6468802B1 (en) * | 1998-05-06 | 2002-10-22 | Isotechnika, Inc. | 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control |
| DE10202893A1 (en) * | 2002-01-25 | 2003-08-07 | Inst Chemo Biosensorik | Method for the specific determination of methylglyoxal in liquid and / or gaseous samples |
-
2000
- 2000-06-09 DE DE10028548A patent/DE10028548C1/en not_active Expired - Fee Related
-
2001
- 2001-05-29 US US10/297,424 patent/US6884223B2/en not_active Expired - Fee Related
- 2001-05-29 JP JP2002502440A patent/JP2004501366A/en active Pending
- 2001-05-29 WO PCT/EP2001/006101 patent/WO2001094942A1/en active IP Right Grant
- 2001-05-29 AU AU2001263943A patent/AU2001263943A1/en not_active Abandoned
- 2001-05-29 KR KR1020027016648A patent/KR20030014691A/en not_active Application Discontinuation
- 2001-05-29 DE DE50101715T patent/DE50101715D1/en not_active Expired - Fee Related
- 2001-05-29 AT AT01938242T patent/ATE262179T1/en not_active IP Right Cessation
- 2001-05-29 EP EP01938242A patent/EP1287356B1/en not_active Expired - Lifetime
- 2001-05-29 RU RU2002132381/15A patent/RU2002132381A/en not_active Application Discontinuation
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3792272A (en) * | 1973-01-12 | 1974-02-12 | Omicron Syst Corp | Breath test device for organic components, including alcohol |
| US3792272B1 (en) * | 1973-01-12 | 1986-07-22 | ||
| US5174959A (en) * | 1986-12-22 | 1992-12-29 | Abbott Laboratories | Breath component monitoring device |
| US5601079A (en) * | 1992-03-12 | 1997-02-11 | Wong; Jacob Y. | Non-invasive quantification of glucose control, aging, and advanced maillard products by stimulated fluorescence |
| US5618734A (en) * | 1993-09-29 | 1997-04-08 | Kureha Chemical Industry Co., Ltd. | Method for measuring 3-deoxyglucosone derivatives in a sample |
| US6620107B2 (en) * | 1997-03-06 | 2003-09-16 | Osmetech Plc | Detection of conditions by analysis of gases or vapours |
| US6467333B2 (en) * | 1998-06-19 | 2002-10-22 | California Institute Of Technology | Trace level detection of analytes using artificial olfactometry |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080210879A1 (en) * | 2005-07-11 | 2008-09-04 | Maintenance Securite Installation Service | Method for Controlling Leakage Rate of Active Carbon Filters |
Also Published As
| Publication number | Publication date |
|---|---|
| DE10028548C1 (en) | 2001-08-30 |
| EP1287356B1 (en) | 2004-03-17 |
| WO2001094942A1 (en) | 2001-12-13 |
| DE50101715D1 (en) | 2004-04-22 |
| AU2001263943A1 (en) | 2001-12-17 |
| ATE262179T1 (en) | 2004-04-15 |
| JP2004501366A (en) | 2004-01-15 |
| KR20030014691A (en) | 2003-02-19 |
| RU2002132381A (en) | 2004-04-27 |
| EP1287356A1 (en) | 2003-03-05 |
| US6884223B2 (en) | 2005-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6491643B2 (en) | Breath test analyzer | |
| US6468802B1 (en) | 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control | |
| Moyer et al. | Analysis for urinary catecholamines by liquid chromatography with amperometric detection: methodology and clinical interpretation of results. | |
| EP0272552B1 (en) | Method and device for ketone measurement | |
| US6479019B1 (en) | Sensor and sensor assembly for detecting a target gas in a breath sample | |
| Eberts et al. | A simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol. | |
| US6884223B2 (en) | Method for detecting α-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient | |
| JPH0113062B2 (en) | ||
| Velghe et al. | Opening the toolbox of alternative sampling strategies in clinical routine: a key-role for (LC-) MS/MS | |
| CN108802250B (en) | Method for detecting 11 neurotransmitters in brain microdialysis solution by ultra-high performance liquid chromatography-mass spectrometry | |
| EP1018938B1 (en) | Breath test analyser | |
| USRE38728E1 (en) | Breath test analyzer | |
| US20060133999A1 (en) | Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method | |
| CN202018425U (en) | Device used for measuring acetone in respiratory gas | |
| CN101446582A (en) | 1, 5-anhydroglucitol assay kit and assay method thereof | |
| CN101419224B (en) | Method for simultaneously determining mycophenolic acid ester, mycophenolic acid and metabolite thereof in human blood plasma | |
| CN111812237A (en) | Valproic acid drug concentration detection kit and application thereof | |
| JPH1151934A (en) | Analytical method and analyzer for biological component | |
| KR102081522B1 (en) | Blood analysis method and blood test kit | |
| JP2009133803A (en) | Identifying technique of liver fibrotic level and carbohydrate medicine imagery molecule imaging agent therefor | |
| EP4353829A1 (en) | Method for quantifying phenylalanine in blood, and measurement kit used therefor | |
| Harger | Recently published analytical methods for determining alcohol in body materials-Alcohol Countermeasures Literature Review | |
| Velghe | Therapeutic drug monitoring in the dried spotlight | |
| JPH0862220A (en) | Highly sensitive measuring method and apparatus for sugar and polyoles | |
| IL121751A (en) | Breath test analyzer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: INSTITUT FUR CHEMO-UND BIOSENSORIK MUNSTER E.V., G Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KLEIBOHMER, WOLFGANG;SCHULZE-PELLENGAHR, UTA;REEL/FRAME:014381/0950 Effective date: 20021219 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20090426 |